Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Helsinki to welcome 270 cruise ships this summer

Cruise ships will bring an estimated 440,000 visitors to Helsinki.©: Lauri Rotko The 2017 cruise season begins on Wednesday 3 May with the arrival of Astor to the Katajanokka Quay next to the Allas Sea Pool in the centre of Helsinki. The upcoming cruise season is expected to even busier than last summer. On the basis of advance bookings, Helsinki expects to welcome 270 international cruise ships in 2017. They will carry with them an estimated 440,000 visitors, who will get to enjoy the cultural activities and services on offer this summer in the Finnish capital. “Cruise

Otsuka and Lundbeck announce improvement of agitation symptoms related to Alzheimer’s-type dementia following treatment with brexpiprazole relative to placebo

Valby, Denmark, 2 May 2017 - H. Lundbeck A/S (Lundbeck) and Otsuka Pharmaceutical Co., Ltd. (Otsuka) announce top-line results from two phase III clinical trials evaluating the efficacy, safety and tolerability of brexpiprazole in the treatment of agitation in patients with dementia of the Alzheimer’s type.The primary endpoint of both trials was change from baseline in the Cohen-Mansfield Agitation Inventory (CMAI) total score, a 29-item scale to systematically assess the symptoms of agitation[i]. The key secondary endpoint was the change from baseline in the Clinical Global Impression-

New book about safety of journalists in focus at World Press Freedom Day

Journalists are threatened and killed around the world when exercising their right to freedom of expression. At the celebration of the World Press Freedom Day the book The Assault on Journalism. Building knowledge to protect freedom of expression will be launched. The book is one of the first global research work on safety of journalists.The book is the result of a collaboration between University of Gothenburg, UNESCO and the International Association for Media and Communication Research (IAMCR). “People who exercise their right to freedom of expression through journalism must be

Digitisation increasing number of seedlings

Södra has now completed an investment of SEK 10 million in the nursery at Flåboda. The investment will enable more digitised production and increase capacity by 20 percent, from ten million to twelve million seedlings per year.“The increased digitisation of the nursery, including more computer-controlled platforms, will be highly significant for raising the quality and quantity of production. The nursery’s resources can be used more effectively, which will help us improve our contribution to ensuring new forests in Sweden,” said Ida Karlsson, Manager of Södra’s nursery at Flåboda. The

Atlas Copco announces Epiroc as name of the company to be dividended out in 2018

Stockholm, Sweden, May 2, 2017: Atlas Copco, a leading provider of sustainable productivity solutions, has decided that Epiroc will be the name of the company that the Group will dividend out in 2018 provided shareholder approval.“With Epiroc we have found a short, distinct and timeless name that is spot on for the mining and civil engineering business,” said Annika Berglund, Senior Vice President Corporate Communications and Governmental Affairs. On January 16, 2017, Atlas Copco Board of Directors announced that it will prepare a proposal to the Annual General Meeting 2018 to split the

Notice of Annual General Meeting of Net Gaming Europe AB (publ)

The shareholders of Net Gaming Europe AB (publ), 556693-7255, are hereby given notice of the Annual General Meeting at 10 a.m. on Tuesday 30 May 2017 at Advokatfirma DLA Piper Sweden’s premises at Kungsgatan 9 in Stockholm.Notification of attendance etc.Shareholders wishing to attend the AGM must be registered in Euroclear AB’s share register as at Tuesday 23 May 2017, and must send written notification, no later than Friday 26 May 2017, to Net Gaming Europe AB (publ), Box 7385, 103 91 Stockholm, Sweden or by e-mail to info@netgaming.se. The notification must include the full name,

Finnair and Finavia test face recognition technology at Helsinki Airport check-in

Finnair and Finavia, together with Futurice, will test the use of face recognition technology for the check-in process of Finnair flights at Helsinki Airport. During the test period taking place between May 2 until May 23, the companies will gather information on the applicability of face recognition technology to the airport environment and the systems and processes used by the airline. Finnair has invited a group of 1,000 frequent flyers to take part in the test.  “Face recognition technology could offer possibilities for smoothening the departure process from the customer’s point of

Dumper wagon system from Kiruna Wagon named finalist for Swedish Steel Prize 2017

For developing the Helix Dumper, an innovative wagon solution that is highly durable and far more efficient than other ore wagon offerings, Kiruna Wagon has been named a finalist for the Swedish Steel Prize 2017. The Swedish Steel Prize is an international prize that honors the art of engineering and innovation in the steel industry. Kiruna Wagon from Sweden, is one of four finalists for this year’s prize, which will be awarded during a ceremony in Stockholm, Sweden on May 11. “Our customer had found a small design that they wanted to make into a large dedicated wagon concept.

Navamedic ASA: Enters into partnership agreement with Orexigen Therapeutics for Nordic launch of Mysimba®

Oslo, May 2, 2017 - Navamedic ASA (OSE: NAVA), the Norwegian medtech and pharmaceutical products company, today announced it has entered into a five-year agreement with Orexigen Therapeutics Ireland, Ltd., the subsidiary of the American biopharmaceutical company Orexigen Therapeutics, Inc. (Nasdaq: OREX), for Nordic marketing and distribution of Mysimba®, a prescription pharmaceutical. "We are very pleased to announce the agreement with Orexigen Therapeutics for distribution of the prescription anti-obesity pharmacutical Mysimba (naltrexone HCl/bupropion HCl prolonged release), in the

The Frankenstein Factor in IT – Therapy needed for our AI Future

New report on Machine Intelligence by SogetiLabs addressing the fear of Artificial Intelligence and how organizations should handle it.Paris, France, 2 May, 2017 – We are on the threshold of an extraordinary development that makes the automation heart beat faster. Recent announcements by both Facebook and tech pioneer Elon Musk to build brain interfaces are great examples. But together with the expanding possibilities of Artificial Intelligence (AI), emotions run higher and higher. A new report from SogetiLabs 'The Frankenstein Factor: the Anatomy of Fear of AI' recommends taking these

Alfa Laval wins SEK 210 million energy-efficiency order in China

Alfa Laval – a world leader in heat transfer, centrifugal separation and fluid handling – has won an order to supply compact heat exchangers to a refinery in China. The order has a value of approximately SEK 210 million. It is booked in the Welded Heat Exchangers unit of the Energy Division, with deliveries scheduled for 2018.The heat exchangers will be used to recover energy and to increase the yield in the refinery. “I am pleased to announce this large order for our energy-efficient compact heat exchangers,” says Susanne Pahlén Åklundh, President of the Energy Division. “We have a wide

Automatic redemption program and new ISIN codes for NetEnt

The last day of trading in shares of NetEnt including the right to redemption shares is May 3, 2017, and the record date for entitlement to redemption shares is May 5. The ISIN codes of the ordinary NetEnt shares will be changed on May 4, 2017.Following a decision at the Annual General Meeting on April 21, 2017, an automatic redemption program is taking place in NetEnt AB (publ). Each NetEnt share will be split into two new shares, one of which will be a redemption share. Each redemption share will be automatically redeemed at 2.25 SEK in cash. The last day of trading in NetEnt shares

The Frankenstein Factor in IT – Therapy needed for our AI Future

New report on Machine Intelligence by SogetiLabs addressing the fear of Artificial Intelligence and how organizations should handle it.Paris, France, 2 May, 2017 – We are on the threshold of an extraordinary development that makes the automation heart beat faster. Recent announcements by both Facebook and tech pioneer Elon Musk to build brain interfaces are great examples. But together with the expanding possibilities of Artificial Intelligence (AI), emotions run higher and higher. A new report from SogetiLabs 'The Frankenstein Factor: the Anatomy of Fear of AI' recommends taking these

NeuroVive invitation to conference call and web cast on in-licensing agreement with Yungjin Pharm

Lund, Sweden, 2 May 2017 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) (“NeuroVive”) invites to a conference call and webcast tomorrow, 3 May 2017, at 2:00 pm CEST, to present the in-licensing agreement with Yungjin Pharm that was announced this morning.Erik Kinnman, CEO, and Magnus Hansson, CMO, will be presenting and will be available for questions after the presentation. To listen to the presentation please visit: https://tv.streamfabriken.com/neurovive-2017-05-03-pressconference/register To join the conference call and ask questions, please dial: SE:

Kamux Oyj: The Finnish language listing prospectus of Kamux Corporation approved by the Finnish Financial Supervisory Authority has been published

KAMUX CORPORATION         STOCK EXCHANGE RELEASE        2 May 2017 at 9:30 am Not for publication, distribution or release, in whole or in part, directly or indirectly, in or into the United States, Australia, Canada, Hong Kong, Japan, New Zealand, South Africa or Singapore or any other country where it would be against the law.   The Finnish language listing prospectus of Kamux Corporation approved by the Finnish Financial Supervisory Authority has been published The Finnish Financial Supervisory Authority has on April 28, 2017 approved Kamux Corporation's ("Kamux" or the "

Kamux Oyj: Kamux Corporation has applied for its shares to be listed on the main market of Nasdaq Helsinki Ltd

KAMUX CORPORATION         STOCK EXCHANGE RELEASE        2 May 2017 at 9:30 am   Not for publication, distribution or release, in whole or in part, directly or indirectly, in or into the United States, Australia, Canada, Hong Kong, Japan, New Zealand, South Africa or Singapore or any other country where it would be against the law.   Kamux Corporation has applied for its shares to be listed on the main market of Nasdaq Helsinki Ltd Kamux Corporation ("Kamux" or the "Company") has today submitted a listing application with Nasdaq Helsinki Ltd ("Helsinki Stock Exchange") to list

Sectra signs contract with US cancer center for enterprise imaging

Linköping, Sweden and Shelton, CT – May 2, 2017 – International medical imaging IT and cybersecurity company Sectra  (STO: SECT B) announces that it has signed a multi-year contract with City of Hope to install the Sectra Enterprise Image Management suite of products for display, transmission, and storage of all images throughout the healthcare system. The multi-departmental PACS and VNA solution, integrated with the Epic EMR, will enable physicians access and sharing of images and information across the entire clinical pathway.City of Hope is one of only forty-seven

Genovis expands its product portfolio and launches FabALACTICA™

Genovis is expanding its product portfolio and launching yet another unique enzyme for antibody analysis, FabALACTICA™. This enzyme is of particular interest to pharmaceutical companies that develop biological drugs in the growing immunotherapy segment. With the launch of FabALACTICA Genovis will have nine unique enzymes for antibody analysis in the product portfolio, as well as one product for labeling antibodies.Development of new biological drugs in the immunotherapy segment is undergoing strong growth. New types of therapeutic antibodies place new demands on the reagents used for

Tor Berthelius joins Beringer Finance

Tor Berthelius joins Beringer Finance as Country Manager for Sweden and will be part of the firm’s Executive Management Team.“We are extremely pleased to welcome Tor to Beringer Finance. He has considerable experience and is highly regarded in the industry. Upon joining he will be focusing on client relationships as well as expanding our Stockholm office. With a new Country Manager in place in Sweden taking over my role there, and Einar U. Johansen as Country Manager in Norway and Deputy CEO, I will now be able to fully focus on the overall development of Beringer Finance”, says Adalsteinn

Invitation to presentation of Nordic Waterproofing’s first quarter 2017 report

Nordic Waterproofing Holding A/S will publish its interim report for January–March 2017 on Tuesday, 9 May 2017 at approximately 08:00 a.m. CET. A conference call and web presentation for investors, analysts and media will be held the same day, at 10:00 a.m. CET.The CEO, Mr. Martin Ellis and the CFO, Mr. Jonas Olin, will present and comment the report as well as answer questions following the presentation. The presentation will be held in English via a telephone conference and a live webcast will be available on www.nordicwaterproofing.com 

Clavisters CEO has bought shares in the company

Clavister (NASDAQ: CLAV) today announced that Clavisters CEO Johan Öhman has  bought 15,600 shares in Clavister. Öhmans shareholding in the company amounts to 22,100 after the transaction. For more information, please contact:Johan Öhman, CEO and  president Phone:+46 727 11 73 73Mail: johan.ohman@clavister.com About Clavister Clavister is a leading supplier of software for virtual security with high performance. Its award winning system offers the highest level of protection with unmatched reliability. Clavister was founded in 1997 and offers its solutions globally through a

Camurus and Braeburn Pharmaceuticals Announce Positive Top-line Results from Long-term Phase 3 Safety Study of CAM2038

New data support long-term safety and efficacy of weekly and monthly subcutaneous buprenorphine depots in patients with opioid use disorderLund, Sweden and Princeton, New Jersey — 2 May 2017 — Camurus (NASDAQ STO: CAMX) and Braeburn Pharmaceuticals today announced positive top-line results from a long-term Phase 3 trial supporting the safety and efficacy of CAM2038 (weekly and monthly buprenorphine depots) in patients with moderate-to-severe opioid use disorder. “These new Phase 3 results add to the growing body of evidence supporting the use of our weekly and monthly buprenorphine

There are no items matching the current filter
There are no more items matching the current filter
Back to top